MRSN

Mersana Therapeutics Inc

MRSN.US mersana.com + Research + Basket
CIK 0001442836
Employees 102
Phone 617 498 0020
Fiscal year end December
IPO Jun 28, 2017
Address 840 Memorial Drive, Cambridge, MA, United States, 02139
Price N/A
USD · NASDAQ
52-week range
7.54
30.39
Market Cap
145.36M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-11.91
Div. Yield
N/A
% Institutions
67.57%
% Insiders
1.47%

1 Year

-14.5%

3 Year

-79.0%

10 Year

-91.7%
Description

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. As of January 6, 2026, Mersana Therapeutics, Inc. operates as a subsidiary of Day One Biopharmaceuticals, Inc.

Actions

Add an action for MRSN.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Martin H. Huber M.D. President, CEO & Director 1960
Mr. Brian C. DeSchuytner Senior VP, CFO & COO 1978
Dr. Timothy B. Lowinger Ph.D. Senior VP and Chief Science & Technology Officer 1964
Ms. Alejandra Veronica Carvajal J.D. Senior VP, Secretary & Chief Legal Officer 1974
Dr. Mohan Bala Ph.D. Senior VP & Chief Development Officer 1965
Mr. Mikhail Papisov Ph.D. Co-Founder NA
Mr. Ashish Mandelia VP & Chief Accounting Officer 1975
Mr. Chuck Miller Senior Vice President of Regulatory Affairs NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Oct 27, 2025 Mohan Bala N/A Sale 77.00 $9.90 $762.30 SEC
Sep 12, 2025 Martin H Jr. Huber N/A Sale 2.01K $7.31 $14.71K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Nextech Invest, Ltd. 12.07M Mar 31, 2025 9.67% $0.97 0.00%
Bain Capital Life Sciences Investors, LLC 8.66M Mar 31, 2025 6.94% $0.44 0.00%
Vanguard Group Inc 8.38M Mar 31, 2025 6.71% $0.00 18.71%
BlackRock Inc 8.33M Mar 31, 2025 6.67% $0.00 -9.55%
Schonfeld Strategic Advisors LLC 7.61M Mar 31, 2025 6.10% $0.02 259.22%
AQR Capital Management LLC 5.14M Mar 31, 2025 4.12% $0.00 0.00%
Rock Springs Capital Management LP 3.81M Mar 31, 2025 3.06% $0.08 11.16%
SILVERARC CAPITAL MANAGEMENT, LLC 3.09M Mar 31, 2025 2.48% $0.22 0.00%
State Street Corp 2.60M Mar 31, 2025 2.09% $0.00 -5.82%
Geode Capital Management, LLC 2.44M Mar 31, 2025 1.96% $0.00 0.00%
Catalio Capital Management, LP 1.71M Mar 31, 2025 1.37% $0.14 0.00%
683 Capital Management LLC 1.65M Mar 31, 2025 1.32% $0.04 83.33%
Jacobs Levy Equity Management, Inc. 1.33M Mar 31, 2025 1.07% $0.00 19.89%
5AM Venture Management, LLC 1.31M Mar 31, 2025 1.05% $0.17 0.00%
Qube Research & Technologies 1.17M Mar 31, 2025 0.94% $0.00 238.10%
Northern Trust Corp 864.79K Mar 31, 2025 0.69% $0.00 -6.98%
Renaissance Technologies Corp 839.92K Mar 31, 2025 0.67% $0.00 38.54%
Deutsche Bank AG 839.72K Mar 31, 2025 0.67% $0.00 0.00%
IEQ CAPITAL, LLC 707.02K Mar 31, 2025 0.57% $0.00 0.00%
Lion Point Capital, LP 644.00K Mar 31, 2025 0.52% $1.41 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Explorer Inv 2.01M 1.61% ▲ 0.00% Jun 30, 2025
2 Vanguard VIF Small Co Gr 408.39K 0.33% ▲ 0.00% Jun 30, 2025
3 Extended Equity Market Fund K 208.93K 0.17% ▼ 1.96% Jun 30, 2025
4 Vanguard Total Stock Mkt Idx Inv 135.87K 2.72% ▼ 2.14% Jul 31, 2025
5 Vanguard Market Neutral I 118.12K 0.09% ▲ 0.00% Jun 30, 2025
6 NT Ext Equity Mkt Idx Fd - L 105.84K 0.08% ▲ 0.00% Jun 30, 2025
7 Northern Trust Extended Eq Market Idx 105.84K 0.08% ▲ 0.00% Jun 30, 2025
8 NT Ext Equity Mkt Idx Fd - NL 86.39K 0.07% ▲ 0.00% Jun 30, 2025
9 NT Ext Equity Mkt Idx Fd - DC - NL - T2 67.08K 0.05% ▼ 0.25% Jun 30, 2025
10 NT Col R2000 Val Idx Fd -DC -L -TierFour 56.40K 0.05% ▼ 49.73% Mar 31, 2025

Financial Highlights

▼
Market Cap: $145.36M
EBITDA: $-66.29M
PEG Ratio: $0.00
Book Value: $-11.91
Earnings/Share: $-13.95
Profit Margin: -211.22%
Operating Margin: -67.91%
ROA (TTM): -36.27%
ROE (TTM): -505.14%
Revenue (TTM): $33.18M
Revenue/Share (TTM): $6.67
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -12.60%

Valuation Metrics

Enterprise Value: $91.27M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 5.00M
Shares Float: 3.53M
% Insiders: 1.47%
% Institutions: 67.57%
Short % Float: 1.19%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$40.50M
Cost of Goods Sold
adjust
$-1.63M
Gross Profit
subtotal
$40.50M
SG&A
adjust
$-40.81M
R&D
adjust
$-73.02M
Operating Income
subtotal
$-73.34M
Other / Non-Operating Items
adjust
$4.14M
Net Income
subtotal
$-69.19M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about MRSN.US!